Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsGold Coast Rebyota Prior Auth Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentGold Coast Health PlanPolicy N/A

    Rebyota Coverage Criteria

    Customize your policy alerts

    Sign up for all goldcoasthealthplan policy alerts

    Know when goldcoasthealthplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and Medicare Part B coverage for Rebyota (fecal microbiota live-jslm) for members aged 18 years or older following antibiotic treatment for recurrent Clostridioides difficile infection.

    Policy Summary
    PayerGold Coast Health Plan
    PolicyRebyota Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateAug 21, 2025
    Last ReviewAug 21, 2025
    Next Review DateN/A
    Key ActionSubmit medical records documenting the covered indication, age of at least 18 years, prior antibiotic treatment for recurrent CDI, and prior therapies and responses to treatment.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    18+Minimum member age
    1 courseCoverage duration
    J1440HCPCS billing code
    150 mLSupplied volume
    None

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Uses outside FDA indication

    Rebyota Coverage Criteria

    Initial Rebyota coverage

    Covered when all of the following are met:

    Covered use requirements

    • Indication: Rebyota is requested to prevent recurrence of Clostridioides difficile infection following antibiotic treatment for recurrent CDI.
    • Age requirement: The individual is 18 years of age or older.>= 18 years

    Uses of Rebyota outside the FDA-labeled indication—prevention of recurrence of Clostridioides difficile infection (CDI) following antibiotic treatment for recurrent CDI—are excluded from coverage. No compendia-supported uses have been identified for this therapy beyond the FDA indication.

    Initial Rebyota Authorization Criteria

    Initial Rebyota authorization

    Initial treatment is covered when all of the following are met:

    Initial therapy criteria

    • FDA-labeled indication: Rebyota is requested to prevent recurrence of Clostridioides difficile infection following antibiotic treatment for recurrent CDI.
    • Age requirement: The individual is 18 years of age or older.>= 18 years
    • Supporting medical records: Medical records supporting the request, including documentation of prior therapies and responses to treatment, are submitted.

    Billing and Coding

    Covered HCPCS CodesHCPCSCovered
    J1440Rebyota (fecal microbiota live-jslm) Billing unit: 1 ml 150ml Rectal Suspension

    Prior Authorization and Documentation

    Prior Authorization

    Submit complete Rebyota prior authorization

    Prior authorization criteria apply to Rebyota. The request must document the covered indication, member age of at least 18 years, prior antibiotic treatment for recurrent CDI, and prior therapies and responses to treatment.

    • Prevention of recurrence of Clostridioides difficile infection following antibiotic treatment for recurrent CDI
    • Member is 18 years of age or older
    • Prior therapies and responses to treatment are documented
    Documentation Required

    Provide medical records and treatment history

    Submit medical records supporting the request, including documentation of prior therapies and responses to treatment.

    • Include records of prior therapies

    Rebyota Overview

    Rebyota (fecal microbiota live-jslm) is indicated for the prevention of recurrence of Clostridioides difficile infection (CDI) in adults 18 years of age and older following antibiotic treatment for recurrent CDI. It is supplied as a 150 mL rectal suspension.

    Key Terms

    Definitions
    AbbreviationCDI
    Full termClostridioides difficile infection
    Policy contextPrevention of recurrence following antibiotic treatment for recurrent CDI

    Course and Quantity Limit

    Quantity Limits
    Treatment limitOne treatment course
    Coverage basisPer FDA label and/or accepted standards of medical practice
    Product supplied150 mL rectal suspension
    Policy Summary
    PayerGold Coast Health Plan
    PolicyRebyota Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateAug 21, 2025
    Last ReviewAug 21, 2025
    Next Review DateN/A
    Key ActionSubmit medical records documenting the covered indication, age of at least 18 years, prior antibiotic treatment for recurrent CDI, and prior therapies and responses to treatment.
    SourceLink
    On This Page
    Rebyota Coverage CriteriaInitial Rebyota Authorization CriteriaBilling and CodingPrior Authorization and DocumentationRebyota OverviewKey TermsCourse and Quantity Limit
  1. Document responses to treatment
  2. Denial Risk

    Avoid unsupported indications or age exceptions

    Coverage is limited to prevention of recurrence of Clostridioides difficile infection in individuals 18 years of age and older following antibiotic treatment for recurrent CDI. Requests for uses outside the FDA indication are not supported by compendia and may be denied.

    • Covered indication: prevention of recurrent CDI following antibiotic treatment
    • Member must be 18 years of age or older
    Denial Risk

    Missing clinical documentation may result in denial

    Requests without medical records documenting prior therapies and responses to treatment may be denied.

    • Submit medical records supporting the request
    • Document prior therapies and responses to treatment